Last reviewed 2026-04-20 · How we verify

HER2 directed therapy

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Anorexia
• Nausea
• Fatigue
• Weight loss
• Cough
• Vomiting
• Colitis
• Diarrhea
• Constipation
• Headache
• Rash maculo-papular
• Dizziness

Key clinical trials

• HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
• A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) (NA)
• Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) (PHASE1, PHASE2)
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (PHASE2)
• Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases (PHASE2)
• Study of DF1001 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
• Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HER2 directed therapy CI brief — competitive landscape report
• HER2 directed therapy updates RSS · CI watch RSS
• Memorial Sloan Kettering Cancer Center portfolio CI